𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Germline copy number variations in BRCA1-associated ovarian cancer patients

✍ Scribed by Kosuke Yoshihara; Atsushi Tajima; Sosuke Adachi; Jinhua Quan; Masayuki Sekine; Hiroaki Kase; Tetsuro Yahata; Ituro Inoue; Kenichi Tanaka

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
262 KB
Volume
50
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We investigated characteristics of germline copy number variations (CNV) in BRCA1‐associated ovarian cancer patients by comparing them to CNVs present in sporadic ovarian cancer patients. Germline CNVs in 51 BRCA1‐associated, 33 sporadic ovarian cancer patients, and 47 healthy women were analyzed by both signal intensity and genotyping data using the Affymetrix Genome‐Wide Human SNP Array 6.0. The total number of CNVs per genome was greater in the sporadic group (median 26, range 12–34) than in the BRCA1 group (median 21, range 11–35; post hoc P < 0.05) or normal group (median 20, range 7–32; post hoc P < 0.05). While the number of amplifications per genome was higher in the sporadic group (median 13, range 7–26) than in the BRCA1 group (median 8, range 3–23; post hoc P < 0.001), the number of deletions per genome was higher in the BRCA1 group (median 12, range 6–24) than in the sporadic group (median 9, range 3–17; post hoc P < 0.01). In addition, 31 previously unknown CNV regions were present specifically in the BRCA1 group. When we performed pathway analysis on the 241 overlapping genes mapped to these novel CNV regions, the ‘purine metabolism’ and ‘14‐3‐3‐mediated signaling’ pathways were over‐represented (Fisher's exact test, P < 0.01). Our study shows that there are qualitative differences in genomic CNV profiles between BRCA1‐associated and sporadic ovarian cancer patients. Further studies are necessary to clarify the significance of the genomic CNV profile unique to BRCA1‐associated ovarian cancer patients. © 2010 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Germline mutations in the BRCA1 and BRCA
Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients
✍ A. Esra Manguoǧlu; Güven Lüleci; Tayfun Özçelik; Taner Çolak; Hagit Schayek; Mus 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB 👁 2 views

In this study we genotyped Turkish breast/ovarian cancer patients for BRCA1/BRCA2 mutations: protein truncation test (PTT) for exon 11 BRCA1 of and, multiplex PCR and denaturing gradient gel electrophoresis (DGGE) for BRCA2, complemented by DNA sequencing. In addition, a modified restriction assay w

BRCA2 germline mutations in Cypriot pati
BRCA2 germline mutations in Cypriot patients with familial breast/ovarian cancer
✍ Andreas Hadjisavvas; Elpida Charalambous; Adamos Adamou; Christina G. Christodou 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB 👁 2 views

Germline mutations in the BRCA2 gene have been shown to be associated with familial female and male breast cancer. Mutations occur throughout the entire coding region of the gene, and there is considerable ethnic and geographical diversity in the deleterious mutations detected in different populatio

Recurrent copy number alterations in BRC
Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways
✍ Karin Leunen; Olivier Gevaert; Anneleen Daemen; Vanessa Vanspauwen; Geneviève Mi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

Array CGH was used to identify recurrent copy number alterations (RCNA) characteristic of either BRCA1-related or sporadic ovarian cancer. After preprocessing, both groups of patients were modeled using a recurrent Hidden Markov Model to detect RCNA. RCNA with a probability higher than 80% were call

Germline mutations of BRCA1 and BRCA2 in
Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families
✍ Hio Chung Kang; Il-Jin Kim; Jae-Hyun Park; Hyuk-Jun Kwon; Yong-Jin Won; Seung Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

Germline mutations in the BRCA1 and BRCA2 genes are responsible for the predisposition and development of familial breast and/or ovarian cancer. Most mutations of BRCA1 and BRCA2 associated with breast and/or ovarian cancer result in truncated proteins. To investigate the presence of BRCA1 and BRCA2

BRCA1 and BRCA2 germline mutations in Ko
BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer
✍ Jae Hong Seo; Dae-Yeon Cho; Se-Hyun Ahn; Kyung-Sik Yoon; Chang-Soo Kang; Hyun Mi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

In order to evaluate the role of BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer, 97 patients with sporadic breast cancer were analyzed for mutations in the BRCA1 and BRCA2 coding regions, by using a combination of fluorescent-conformation sensitive gel electrophore